Session 915

Innovations in Kidney Transplant Patient Care

This discussion will provide an opportunity to learn more about the noninvasive blood test, AlloSure, the only donor-derived, cell-free DNA test with multicenter, prospective clinical validation.

We will also explore:

  1. How AlloSure’s detection of cell free DNA serves as a leading indicator of graft injury
  2. Why AlloSure outperforms serum creatinine
  3. How AlloSure can differentiate ambiguous rejection
Christopher Boshkos, MD

Christopher Boshkos, MD

Medical Director, Kidney Transplantion, CareDx
Matthew R. Weir, MD

Matthew R. Weir, MD

Division Head, Nephrology, University of Maryland School of Medicine
small transparent
Watch here

Session 807 (CME Program)

Diagnosis of Acute Rejection in Kidney Transplantation: a Clinical Update

Tarek Alhamad, MD, MS

Tarek Alhamad, MD, MS

Acute Rejection in Kidney Transplantation: Pathophysiology and Impact on Outcomes
Deirdre Sawinski, MD

Deirdre Sawinski, MD

Diagnostic Modalities for Acute Rejection in Kidney
Jonathan Bromberg

Jonathan Bromberg

Advances in Non-Invasive Diagnosis of Acute Rejection in Kidney Transplantation
Watch here

CME Objectives

After this program, participants will know:

  • The pathophysiology and impact of allograft rejection in kidney transplantation
  • Methods to detect acute rejection in kidney transplantation
  • How to interpret current clinical information on noninvasive biomarker technologies for use in monitoring of acute rejection in kidney transplantation